Figure 1.
Figure 1. Distribution of sialyl 6-sulfo Lex and 6-sulfo Lex determinants on human peripheral lymphocyte subsets. (A) Distribution of sialyl 6-sulfo Lex (G152) determinants on human peripheral lymphocyte subsets. (Left column) Two-dimensional distribution of CD3, CD19, or CD56 and sialyl 6-sulfo Lex in total lymphocytes (2-color analyses). (Middle column) Two-dimensional distribution of CD4 or CD8 and sialyl 6-sulfo Lex in gated CD3+ cells (3-color analyses). (Right column) Two-dimensional distribution of CD45RO or CD45RA and sialyl 6-sulfo Lex on gated CD3+CD4+ cells (4-color analyses). (B) Distribution of nonsialylated 6-sulfo Lex (AG107) determinants on sialidase-treated human peripheral lymphocyte subsets in the same settings.

Distribution of sialyl 6-sulfo Lex and 6-sulfo Lex determinants on human peripheral lymphocyte subsets. (A) Distribution of sialyl 6-sulfo Lex (G152) determinants on human peripheral lymphocyte subsets. (Left column) Two-dimensional distribution of CD3, CD19, or CD56 and sialyl 6-sulfo Lex in total lymphocytes (2-color analyses). (Middle column) Two-dimensional distribution of CD4 or CD8 and sialyl 6-sulfo Lex in gated CD3+ cells (3-color analyses). (Right column) Two-dimensional distribution of CD45RO or CD45RA and sialyl 6-sulfo Lex on gated CD3+CD4+ cells (4-color analyses). (B) Distribution of nonsialylated 6-sulfo Lex (AG107) determinants on sialidase-treated human peripheral lymphocyte subsets in the same settings.

Close Modal

or Create an Account

Close Modal
Close Modal